PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 意见
• 07/08/23
0
0
嵌入
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论